Eli Lilly and Company has announced plans to construct a new $2.5-billion injectable manufacturing site in Alzey, Rhineland-Palatinate, Germany.  

This new facility will further expand the company’s global parenteral (injectable) product and device manufacturing network and support increased demand for Lilly’s medicines, including its diabetes and obesity portfolio.  

With the planned manufacturing facility in Alzey, Lilly will operate a total of six manufacturing sites in Europe, including one in nearby Fegersheim, France.  

Construction is scheduled to begin in 2024. Lilly’s investment in Alzey is contingent upon finalization of government permitting and local approvals. The new site is scheduled to be operational beginning in 2027, and the company expects to employ 1,000 workers at the site, including engineers, operators, and scientists. 

Separately, Lilly is also investing up to $100 million to increase its footprint in Germany’s early-stage biotech ecosystem. These investments will focus on biotech and life-sciences venture capital funds by expanding Lilly’s incubator and accelerator engagements and strengthening Lilly’s ties and activities with academic and innovation partners. 

Source: Eli Lilly and Company